Value-based care for the treatment and evaluation of benign prostatic hyperplasia: an analysis of a metropolitan service area claims database
- 11 February 2020
- journal article
- research article
- Published by Springer Nature in World Journal of Urology
- Vol. 38 (12) , 3245-3250
Abstract
Purpose With an aging population, cost containment and improved outcomes will be crucial for a sustainable healthcare ecosystem. Current data demonstrate great variation in payments for procedures and diagnostic workup of benign prostatic hyperplasia (BPH). To help determine the best financial value in BPH care, we sought to analyze the major drivers of total payments in BPH. Materials and methods Commercial and Medicare claims from the Truven Health Analytics Markestscan® database for the Austin, Texas Metropolitan Service Area from 2012 to 2014 were queried for encounters with diagnosis and procedural codes related to BPH. Linear regression was utilized to assess factors related to BPH-related payments. Payments were then compared between surgical patients and patients managed with medication alone. Results Major drivers of total payments in BPH care were operative, namely transurethral resection of prostate (TURP) [$2778, 95% CI ($2385–$3171), p < 0.001) and photoselective vaporization (PVP) ($3315, 95% CI ($2781–$3849) p < 0.001). Most office procedures were also associated with significantly higher payments, including cystoscopy [$708, 95% CI ($417–$999), p < 0.001], uroflometry [$446, 95% CI ($225–668), p < 0.001], urinalysis [$167, 95% CI ($32–$302), p = 0.02], postvoid residual (PVR) [$245, 95% CI ($83–$407), p < 0.001], and urodynamics [$1251, 95% CI ($405–2097), p < 0.001]. Patients who had surgery had lower payments for their medications compared to patients who had no surgery [$120 (IQR: $0, $550) vs. $532 (IQR: $231, $1852), respectively, p < 0.001]. Conclusion Surgery and office-based procedures are associated with increased payments for BPH treatment. Although payments for surgery were more in total, surgical patients paid significantly less for BPH medications.Keywords
This publication has 17 references indexed in Scilit:
- Cost-effectiveness analysis of six therapies for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasiaClinicoEconomics and Outcomes Research, 2017
- The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A systematic review and meta-analysisScientific Reports, 2017
- Alternative payment models and urologyCurrent Opinion in Urology, 2017
- How Readable Is BPH Treatment Information on the Internet? Assessing Barriers to Literacy in Prostate HealthAmerican Journal of Men's Health, 2016
- Measuring the cost of care in benign prostatic hyperplasia using time-driven activity-based costing (TDABC)Healthcare, 2015
- Benign Prostatic Hyperplasia Evaluation and Management by Urologists and Primary Care Physicians: Practice Patterns From the Observational BPH RegistryJournal of Urology, 2011
- What Is Value in Health Care?New England Journal of Medicine, 2010
- A brief conceptual tutorial of multilevel analysis in social epidemiology: using measures of clustering in multilevel logistic regression to investigate contextual phenomenaJournal of Epidemiology and Community Health, 2006
- ECONOMIC COSTS OF BENIGN PROSTATIC HYPERPLASIA IN THE PRIVATE SECTORJournal of Urology, 2005
- Appropriate Assessment of Neighborhood Effects on Individual Health: Integrating Random and Fixed Effects in Multilevel Logistic RegressionAmerican Journal of Epidemiology, 2005